WuXi Biologics’ licensing deals help offset Biosecure threat in the US
WuXi Biologics attributed a 32.5% increase in North American revenue last year to out-licensing deals with global drugmakers despite the "dynamic political environment” in the US. That’s compared to 20.2% revenue growth for the Chinese ...
WuXi Biologics attributed a 32.5% increase in North American revenue last year to out-licensing deals with global drugmakers despite the "dynamic political environment” in the US.
That’s compared to 20.2% revenue growth for the Chinese ...
